Pseudomonas aeruginosa Infections Clinical Presentation

  • Author: Klaus-Dieter Lessnau, MD, FCCP; Chief Editor: Michael Stuart Bronze, MD   more...
 
Updated: Jan 11, 2012
 

History

Pseudomonal infections can involve any part of the body.

  • Respiratory tract
    • Pneumonia is observed in patients with immunosuppression and chronic lung disease. It can be acquired nosocomially in the intensive care unit (ICU) setting and is associated with positive-pressure ventilation and endotracheal tubes. The pneumonia may be primary, following aspiration of the organism from the upper respiratory tract, especially in patients on mechanical ventilation. Alternatively, it may occur as a result of bacteremic spread to the lungs. This is observed commonly in patients following chemotherapy-induced neutropenia.
    • Bacteremic pneumonia occurs in patients with neutropenia following chemotherapy and in patients with AIDS.
    • Chronic infection of the lower respiratory tract with P aeruginosa is prevalent among patients with cystic fibrosis. These patients may present with chronic productive cough, anorexia, weight loss, wheezing, and tachypnea.[3]
    • Symptoms of pneumonia include fever, chills, severe dyspnea, cyanosis, productive cough, confusion, and other signs of a systemic inflammatory response.
  • Bacteremia
    • Bacteremia may be acquired via medical devices in hospitals and nursing homes, and the mortality rate remains greater than 10%.
    • Signs and symptoms depend on the primary site of infection.
  • Endocarditis
    • P aeruginosa may infect native heart valves in individuals who abuse intravenous drugs and may infect prosthetic heart valves.
    • Right-sided and left-sided valve infections may occur.
    • Nonspecific symptoms include fever and malaise, with more specific symptoms depending on which cardiac valve is involved. Left-sided endocarditis typically presents with symptoms of congestive heart failure and those resulting from systemic spread of septic emboli.
  • Central nervous system
    • P aeruginosa infection can cause meningitis and brain abscess.
    • Most infections follow an extension from a contiguous parameningeal structure, such as an ear, a mastoid, paranasal sinus surgery, or diagnostic procedures. In some patients, the involvement of the CNS is due to hematogenous spread of the organism from infective endocarditis, pneumonia, or UTI.
    • Patients present with fever, headache, and confusion. The onset may be fulminant or subacute, often depending on the immune status of the patient.
  • Ear
    • In otitis externa (swimmer's ear), patients present with pain, pruritus, and ear discharge. The pain is worsened by traction on the pinna.
    • Pseudomonas infection is a common cause of chronic otitis media. Malignant otitis externa is a manifestation of invasive infection predominantly observed in patients with uncontrolled diabetes. It begins as ordinary otitis externa that fails to respond to antibiotic therapy. Presenting symptoms are persistent pain, edema, and tenderness of the soft tissues of the ear, with a purulent discharge. Fever is uncommon, and some patients present with a facial nerve palsy. Extension of the infection to the temporal bone can result in osteomyelitis, and further extension can create cranial nerve palsies and possibly a CNS infection.
  • Eye
    • The cornea, aqueous humor, and vitreous humor comprise an immunocompromised environment, and Pseudomonas, when introduced, produces extracellular enzymes that cause a rapidly progressive and destructive lesion. P aeruginosa is a common cause of bacterial keratitis, scleral abscess, and endophthalmitis in adults and ophthalmia neonatorum in children.
    • Predisposing conditions for corneal involvement are trauma, contact lens use, predisposing ocular conditions, exposure to an ICU environment, and AIDS. Corneal lesions can progress to endophthalmitis and orbital cellulitis. Symptoms are pain, redness, swelling, and impaired vision.
  • Bones and joints
    • The most common sites of involvement are the vertebral column, the pelvis, and the sternoclavicular joint.
    • Infection may be blood-borne, as in individuals who abuse intravenous drugs or in patients with pelvic infections or UTI. Alternatively, the infection may be contiguous, related to penetrating trauma, surgery, or overlying soft tissue infections. Patients at risk for pseudomonal bone and joint infections include those with puncture wounds to the foot, peripheral vascular disease, intravenous drug abuse, or diabetes mellitus.
    • Vertebral osteomyelitis may involve the cervical spine, and patients present with neck or back pain lasting weeks to months. Occasionally, patients with complicated UTI may develop lumbosacral vertebral osteomyelitis.
    • Patients with pyoarthrosis present with swelling and pain in the affected joint. Patients are persistently febrile.
  • Gastrointestinal
    • Pseudomonal infections can affect every portion of the GI tract. The disease is often underestimated but usually affects very young children and adults with hematologic malignancies and chemotherapy-induced neutropenia. Additionally, colonization of the GI tract is an important portal of entry for pseudomonal bacteremia in patients who are neutropenic. The spectrum of disease can range from very mild symptoms to severe necrotizing enterocolitis with significant morbidity and mortality.
    • Epidemics of pseudomonal diarrhea can occur in nurseries. Young infants may present with irritability, vomiting, diarrhea, and dehydration.
    • The infection can cause enteritis, with patients presenting with prostration, headache, fever, and diarrhea (Shanghai fever).
    • Pseudomonas typhlitis typically presents in patients with neutropenia resulting from acute leukemia, with a sudden onset of fever, abdominal distension, and worsening abdominal pain.
  • Urinary tract infections
    • Pseudomonal UTIs are usually hospital-acquired and are associated with catheterization, instrumentation, and surgery.
    • These infections can involve the urinary tract through an ascending infection or through bacteremic spread. In addition, these infections are a frequent source of bacteremia.
    • No specific characteristics distinguish this type of infection from other forms of UTI.
  • Skin
    • Pseudomonas does not grow on dry skin, but it flourishes on moist skin.
    • Green nail syndrome is a paronychial infection that can develop in individuals whose hands are frequently submerged in water.
    • Secondary wound infections occur in patients with decubiti, eczema, and tinea pedis. These infections may have a characteristic blue-green exudate with a fruity odor.
    • Pseudomonas is a common cause of hot tub or swimming pool folliculitis. Patients present with pruritic follicular, maculopapular, vesicular, or pustular lesions on any part of the body that was immersed in water.
    • Pseudomonal bacteremia produces distinctive skin lesions known as ecthyma gangrenosum.
    • Pseudomonas also has emerged as an important source of burn wound sepsis. Invasive burn wound sepsis is defined as the bacterial proliferation of 100,000 organisms per gram of tissue, with subjacent involvement of subjacent unburned tissue.
Next

Physical

  • Endocarditis
    • Cardinal features of bacterial endocarditis include fever, murmur, and positive blood culture findings.
    • A new onset of cardiac murmur or a change in character of a preexisting murmur may develop, although these may be absent on presentation.
    • Peripheral stigmata of endocarditis include Roth spots, Janeway lesions, Osler nodes, splinter hemorrhages, and splenomegaly.
  • Pneumonia
    • Patients have rales, rhonchi, fever, cyanosis, retractions, and hypoxia.
    • Shock may develop in patients with bacteremic pneumonia.
    • Patients with cystic fibrosis may develop clubbing, increased anteroposterior (AP) diameter, and malnutrition.
  • Gastrointestinal tract
    • Young infants with diarrhea may have fever, signs of dehydration, abdominal distension, and signs of peritonitis.
    • Physical findings of Shanghai fever may include fever, splenomegaly, and rose spots. Depending on the severity of the illness, prostration, dehydration, and vascular collapse may be observed.
  • Skin and soft tissue infections
    • Ecthyma gangrenosum lesions are hemorrhagic and necrotic, with surrounding erythema. These characteristic lesions are almost always caused by Pseudomonas infection and usually are found in the axilla, groin, or perianal area but may involve any part of body.
    • Subcutaneous nodules, deep abscesses, cellulitis, and fasciitis may also occur.
    • Pseudomonal burn wound infections appear black or as a violaceous discoloration or eschar. Systemic manifestations of burn wound sepsis may include fever or hypothermia, disorientation, hypotension, oliguria, ileus, and leukopenia.
  • Skeletal infections
    • Vertebral osteomyelitis manifests as local tenderness and a decreased range of motion.
    • Osteomyelitis may complicate puncture wounds.
    • Neurological deficits, when present, suggest spinal cord involvement.
  • With eye infections, the physical examination reveals lid edema, conjunctival erythema and chemosis, and severe mucopurulent discharge adherent to an underlying corneal ulcer.
  • Malignant otitis externa
    • The external auditory canal is erythematous, swollen, and inflamed, and a discharge may be observed.
    • The tympanic membrane is hidden from view because of edema and may be ruptured.
    • Local lymphadenopathy may be present.
  • Bacteremia
    • Patients have fever, tachypnea, and tachycardia.
    • Hypotension and shock may develop.
    • Jaundice may occur.
    • Skin shows characteristic skin lesions called ecthyma gangrenosum.
Previous
Next

Causes

  • Pseudomonal bacteremia occurs in association with malignancy, chemotherapy, AIDS, burn wound sepsis, and diabetes.
  • Certain populations of patients are especially susceptible to pseudomonal infections. Predisposing conditions include placement of intravenous lines, severe burns, urinary tract catheterization, surgery, trauma, and premature birth (infants).
  • Conditions predisposing to pseudomonal infections and major manifestations include the following:
    • Diabetes - Malignant otitis externa
    • Drug addiction - Endocarditis, osteomyelitis
    • Leukemia - Sepsis, typhlitis
    • Cancer - Pneumonia, sepsis
    • Burn wound - Cellulitis, sepsis
    • Cystic fibrosis - Pneumonia
    • Surgery involving CNS - Meningitis
    • Tracheostomy - Pneumonia
    • Neonatal period - Diarrhea
    • Corneal ulcer - Panophthalmitis
    • Vascular catheterization - Bacteremia, suppurative thrombophlebitis
    • Urinary catheterization - UTI
Previous
 
 
Contributor Information and Disclosures
Author

Klaus-Dieter Lessnau, MD, FCCP  Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Pratibha Dua, MD, MBBS  Staff Physician, Internal Medicine, United Medical Park

Pratibha Dua, MD, MBBS is a member of the following medical societies: American Medical Association

Disclosure: Nothing to disclose.

Samer Qarah, MD  Pulmonary Critical Care Consultant, Department of Internal Medicine, Division of Pulmonary and Critical Care, The Brooklyn Hospital Center and Cornell University

Samer Qarah, MD is a member of the following medical societies: American College of Critical Care Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Thomas J Marrie, MD  Dean of Faculty of Medicine, Dalhousie University Faculty of Medicine, Canada

Thomas J Marrie, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society for Microbiology, Canadian Infectious Disease Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

John L Brusch, MD, FACP  Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

John L Brusch, MD, FACP is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Eleftherios Mylonakis, MD  Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital

Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD  Professor, Stewart G Wolf Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

References
  1. Pollack M. Pseudomonas Aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. New York, NY: Churchill Livingstone; 2000:2310-27.

  2. Textbook of Bacteriology. Todar's Online Textbook of Bacteriology [serial online]. Accessed 29/12/07. Available at www.textbookofbacteriology.net..

  3. Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. Apr 2010;65(4):286-91. [Medline].

  4. Bitsori M, Maraki S, Koukouraki S, Galanakis E. Pseudomonas aeruginosa urinary tract infection in children: risk factors and outcomes. J Urol. Jan 2012;187(1):260-4. [Medline].

  5. Abuqaddom AI, Darwish RM, Muti H. The effects of some formulation factors used in ophthalmic preparations on thiomersal activity against Pseudomonas aeruginosa and Staphylococcus aureus. J Appl Microbiol. 2003;95(2):250-5. [Medline].

  6. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis. Jul 15 2005;41(2):149-58. [Medline].

  7. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. Sep 2003;47(9):2756-64. [Medline].

  8. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest. Apr 1996;109(4):1019-29. [Medline].

  9. Cunha BA. Clinical relavance of penicillin resistant Streptococcus pneumoniae. Semin Respir Infect. Sep 2002;17(3):204-14. [Medline].

  10. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am. Nov 2006;90(6):1089-107. [Medline].

  11. Cunha BA. Ventilator associated pneumonia: monotherapy is optimal if chosen wisely. Crit Care. 2006;10(2):141. [Medline].

  12. Cunha BA. Multidrug resistant (MDR) Klebsiella, Acinetobacter, and Pseudomonas aeruginosa. Antibiotics for Clinicians. 2006;10:354-355.

  13. Cunha BA. Pseudomonas aeruginosa: resistance and therapy. Semin Respir Infect. 2002;17:231-239. [Medline].

  14. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med. Aug 1999;27(8):1421-8. [Medline].

  15. Fiorillo L, Zucker M, Sawyer D, Lin AN. The pseudomonas hot-foot syndrome. N Engl J Med. Aug 2 2001;345(5):335-8. [Medline].

  16. Garcia-Lechuz JM, Cuevas O, Castellares C, Perez-Fernandez C, Cercenado E, Bouza E. Streptococcus pneumoniae skin and soft tissue infections: characterization of causative strains and clinical illness. Eur J Clin Microbiol Infect Dis. Apr 2007;26(4):247-53. Epub. [Medline].

  17. Gavin PJ, Suseno MT, Cook FV, Peterson LR, Thomson RB Jr. Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin. Diagn Microbiol Infect Dis. Oct 2003;47(2):427-30. [Medline].

  18. Heal CF, Buettner PG, Cruickshank R, Graham D, Browning S, Pendergast J, et al. Does single application of topical chloramphenicol to high risk sutured wounds reduce incidence of wound infection after minor surgery? Prospective randomised placebo controlled double blind trial. BMJ. Jan 15 2009;338:a2812. [Medline].

  19. Hoban DJ, Zhanel GG. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Expert Rev Anti Infect Ther. Dec 2006;4(6):973-80. [Medline].

  20. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest. May 2000;117(5):1434-42. [Medline].

  21. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. May 2003;47(5):1681-8. [Medline].

  22. Klibanov OM, Raasch RH, Rublein JC. Single versus combined antibiotic therapy for gram-negative infections. Ann Pharmacother. Feb 2004;38(2):332-7. [Medline].

  23. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. Apr 2005;49(4):1306-11. [Medline].

  24. Muramatsu H, Horii T, Morita M, Hashimoto H, Kanno T, Maekawa M. Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates. Int J Med Microbiol. Jun 2003;293(2-3):191-7. [Medline].

  25. [Best Evidence] Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2006;(1):CD003344. [Medline].

  26. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest. Jun 2009;135(6):1610-8. [Medline].

  27. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. May 2009;135(5):1223-32. [Medline].

  28. Schoni MH. Macrolide antibiotic therapy in patients with cystic fibrosis. Swiss Med Wkly. May 31 2003;133(21-22):297-301. [Medline].

  29. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. Apr 2009;37(4):1463-9. [Medline].

  30. van Delden C. Pseudomonas aeruginosa bloodstream infections: how should we treat them?. Int J Antimicrob Agents. Nov 2007;30 Suppl 1:S71-5. [Medline].

  31. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med. May 2009;37(5):1777-86. [Medline].

  32. Vonberg RP, Gastmeier P. Isolation of infectious cystic fibrosis patients: results of a systematic review. Infect Control Hosp Epidemiol. Apr 2005;26(4):401-9. [Medline].

  33. Wang S, Kwok M, McNamara JK, Cunha BA. Colistin for multi-drug resistant (MDR) gram-negative bacillary infections. Antibiotics for Clinicians. 2007;11:389-396.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.